HIGHLIGHTS

  • Healius has updated FY26 guidance with Group Underlying EBITDA of between $259 million and $264 million, and Group Underlying EBIT of between $30 million and $35 million.
  • Macquarie Research has a Neutral rating with a price target of A$0.39 — barely above the current price of A$0.37, reflecting limited near-term upside and significant structural challenges.
  • The company is exploring the sale of its Agilex Biolabs division and has engaged UBS to assist in the process, following several unsolicited approaches from credible parties.

Healius Limited (ASX:HLS) is not a stock that appears in many growth portfolios today, but it is very much a company that deserves careful attention from investors seeking to understand the structural challenges facing Australia's pathology sector. The share price has fallen approximately 65.74% over the past year to A$0.37 as of 14 May 2026 — a decline that has compressed the company's Market Capitalisation to a fraction of what it was just twelve months ago. Macquarie Research has a Neutral rating with a price target of A$0.39, implying that the broker sees limited upside from current levels but is not calling for further significant deterioration.

For a company with over 35 years of history as one of Australia's leading healthcare service providers — operating a network of pathology collection centres and laboratories serving millions of Australians — this level of financial distress and share price erosion is both striking and sobering. To understand how Healius arrived at this point, and what the path forward might look like, it is necessary to examine the specific structural pressures that have been building in the pathology sector over several years.

FY2026 Trading Update: Revenue Growing, But Margins Under Severe Pressure

Healius released a trading update on 13 May 2026 that revealed the ongoing tension at the heart of the company's financial position. Pathology volumes grew 1.2% and revenue grew 3.5% in the first half of FY2026. However, for the ten months to April 2026, volumes have actually declined 0.4% while revenue has grown 2.4% — a picture of modest revenue growth masking underlying Volume softness, likely reflecting a shift toward higher-revenue test categories even as total test volumes slip.

The underlying EBITDA guidance for the full year of between $259 million and $264 million, combined with an EBIT range of $30 million to $35 million, tells a story of a Business generating substantial Operating Income in absolute terms but seeing that income compressed by structural cost pressures. The gap between EBITDA and EBIT — in this case roughly $225 to $229 million — reflects the heavy Depreciation load associated with running a nationwide laboratory network, which is a fundamental characteristic of the pathology business model.

The Medicare Indexation Crisis: A Systemic Underfunding Problem

At the core of Healius' financial difficulties is a funding crisis that is industry-wide, not company-specific. The vast majority of pathology services in Australia are funded through Medicare, with fees set by the federal government. For most pathology tests, Medicare funding has been effectively frozen for an extended period, with the 2024-25 Federal Budget only partially restoring indexation for certain test categories. The most recent Federal Budget, delivered in May 2026, contained no new funding for pathology — a result that Healius described in stark terms in its ASX announcement.

The company noted that GP attendances declined 1.5% in the first half of FY2026 and 1.0% in the January-to-March 2026 period. Fewer GP visits means fewer pathology referrals, which flows directly to volume pressure. Changes to Medicare criteria for B12 and urine testing effective 1 July 2025 more than offset the partial indexation increases that had been implemented, further compressing the revenue environment. Healius was direct in its assessment: the pathology sector is receiving no government support to fund significant wage increases, leaving operators to either cut costs — through staff reductions, collection centre closures, and laboratory rationalisation — or pass costs onto patients through out-of-pocket fees.

Fair Work Commission: A Landmark Decision With Significant Financial Consequences

Compounding the Medicare funding pressures is a landmark decision by the Fair Work Commission on gender-based undervaluation in the healthcare and social assistance industries. Pathology collectors received a wage increase from 1 April 2026, which will add approximately $1.8 million to Healius' Q4 FY26 pathology labour costs. Health professionals will receive phased increases over five years in equal instalments commencing 1 July 2026, with a final determination on rates and classifications yet to be delivered.

To contextualise the financial impact: pathology labour costs increased 0.8% for the ten months to April 2026 inclusive of the Fair Work Commission increases, against prior guidance of broadly flat labour costs for FY26. While the absolute dollar impact in the current year is manageable, the multi-year phasing of the health professional wage increases creates a persistent headwind for a sector that is already operating under a funding freeze. For Healius — with over 8,000 employees — the cumulative impact of these increases over the five-year phase-in period will be material.

Strategic Review: Exploring the Sale of Agilex Biolabs

In a significant strategic development, Healius announced that it has engaged UBS Securities Australia Limited to assist in exploring a sale of its Agilex Biolabs division. This follows several unsolicited approaches from credible parties expressing interest in the business. Agilex Biolabs operates as a standalone contract research organisation within the Healius group, providing specialised bioanalytical and biomarker testing services to pharmaceutical companies and research institutions. Revenue from Agilex has been growing strongly, up 13.7% for the year to date — a stark contrast to the volume pressures in the core pathology business.

Management was explicit that any sale of Agilex would not impact Healius' core pathology operations. The strategic rationale for a potential divestiture is straightforward: Agilex is a high-growth, standalone business that may command a Valuation Premium in an outright sale that would not be achievable while embedded within the larger Healius group, which is currently trading at distressed valuations. The proceeds from a sale could be deployed to reduce Debt, fund Investment in the pathology network, or be returned to shareholders. An update on the proposed sale will be provided at the full-year results presentation in August 2026.

Conclusion

Healius is a company operating at the intersection of some of Australia's most pressing healthcare policy debates: the adequacy of Medicare funding for essential diagnostic services, the gender-based undervaluation of healthcare workers, and the long-term sustainability of a pathology sector that plays a critical role in the Australian health system. The 65% decline in the share price over the past year reflects the severity of these structural pressures, and Macquarie's Neutral rating with a near-current-price target acknowledges that the path to recovery is neither clear nor imminent. The potential sale of Agilex Biolabs is the most tangible near-term catalyst available to management, and investors should watch for updates at the August 2026 full-year results presentation. The core pathology business, while challenged, remains a critical national asset that serves millions of Australians — the question is whether the current funding and cost structure is sustainable without government intervention.